TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT

Medical equipments
pharmaceuticals and personal care products
Northern Ireland (UKN)
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: BELFAST HEALTH AND SOCIAL CARE TRUST: "Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityBELFAST HEALTH AND SOCIAL CARE TRUSTScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: BELFAST HEALTH AND SOCIAL CARE TRUST
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for BELFAST HEALTH AND SOCIAL CARE TRUST. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
Not availableNo published reports
Bid counts are not published for this buyer
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 0 active published awards; 0 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityBELFAST HEALTH AND SOCIAL CARE TRUST
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published9 May 2022, 17:52 BST
Last source update9 May 2022, 17:52 BST
Recurring procurementNot published
ClassificationMedical equipments, pharmaceuticals and personal care products
Delivery area
Northern Ireland (UKN)
OCIDocds-h6vhtk-0335bf
What is being bought
Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT
What changed
From the official release history
  1. Status changed to complete
    9 May 2022, 17:52 BST
  2. Official notice release published
    9 May 2022, 17:52 BST
  3. Buyer information updated
    9 May 2022, 17:52 BST
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    Status not published
    Published valueNot published
    Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    9 May 2022, 17:52 BST
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 9 May 2022, 00:00 BST · £1,000,000
Commercial outcome and competition
Awards
Advanced Accelerator Applications (UK & Ireland) Ltd
Not published · Not published · active
Contracts
Procurement of Lutetium (177Lu) oxodetreotide (Luthathera) PRRT
£1,000,000 · signed 9 May 2022, 00:00 BST · active
Bid statisticsNo aggregate bid statistics published
Buyer and organisations in this procedure

BELFAST HEALTH AND SOCIAL CARE TRUST

Contracting authority GB-FTS-4486
View buyer profile
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationaleNo other reasonable alternative or substitute exists for this procurement and the absence of competition is not a result of the artificial narrowing of the parameters of the procurement. Lutetium (177Lu) oxodetreotide (Lutathera) is a licensed radiopharmaceutical for the treatment of unresectable or metastatic, progressive, well-differentiated somatostatin receptor positive gastro-entero-pancreatic neuroendocrine (GEP) tumours in adults. The supplier, Advanced Accelerator Applications (AAA), holds the unique patent and licence for this product. This is the only licenced Peptide Receptor Radionuclide Therapy (PRRT) in Europe.